Previous 10 | Next 10 |
Axonics Modulation Technologies, Inc. (AXNX) Q3 2020 Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President and Chief Financial Officer Conference Call Participants David Lewi...
Axonics Modulation Technologies, Inc. (AXNX) Q3 2020 Earnings Conference Call October 4, 2020 4:20 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants David Lew...
Gainers: [[ALTM]] +54.6%. [[UPWK]] +24.6%. [[QCOM]] +13.2%. [[APHA]] +10.1%. [[MTW]] +9.5%.Losers: [[BLUE]] -13.9%. [[ELF]] -9.4%. [[INGN]] -8.9%. [[AXNX]] -8.7%. [[PING]] -8.7%. For further details see: ALTM, UPWK, AXNX and INGN among after-hours movers
Axonics Modulation Technologies (AXNX): Q3 GAAP EPS of -$0.24 beats by $0.31.Revenue of $35.2M (+2587.0% Y/Y) beats by $12.25M.Shares -6.8%.Press Release For further details see: Axonics Modulation Technologies EPS beats by $0.31, beats on revenue
Axonics generated net revenue of $35.2 million in the third quarter ended September 30, 2020 Over 5,500 patients have been implanted with the Axonics r-SNM System since U.S. commercial launch Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical tec...
Axonics Modulation Technologies (AXNX) submits a supplemental premarket approval ((PMA)) to the FDA, detachable extremity coil magnetic resonance imaging ((MRI)) conditional labeling for 1.5T and 3.0T MR scanners.The FDA previously approved 1.5T and 3.0T MRI conditional labeling with hea...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has submitted a premarket approval (PMA) supplement to ...
ARTISTRY will enroll up to 300 patients across 30 centers in North America and include patients across all four clinical indications for Axonics Therapy Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializi...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report third quarter 2020 financial results and pr...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that Raymond W. Cohen, CEO of Axonics, has be...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...